Cover Image
市場調查報告書

皮黴菌性甲癬的全球市場:2016∼2020年

Global Dermatophytic Onychomycosis Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353156
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
皮黴菌性甲癬的全球市場:2016∼2020年 Global Dermatophytic Onychomycosis Market 2016-2020
出版日期: 2016年02月17日 內容資訊: 英文 57 Pages
簡介

皮黴菌性甲癬,是指甲和甲床的真菌感染疾病。甲癬的治療有清創和藥物治療。清創是花費時間的治療,不過,對消滅真菌感染疾病沒有效果。甲癬的治療屬全身性藥物療法最有效。全球皮膚絲狀真菌指甲甲真菌症市場,預計2016∼2020年以年複合成長率7.44%擴大。

本報告提供全球皮膚絲狀真菌指甲甲真菌症市場現狀與今後的成長預測,各地區趨勢,以及市場趨勢與課題,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 概要:皮黴菌性甲癬

  • 皮黴菌性甲癬的種類
  • 風險因素
  • 管理
  • 流行病學

第6章 開發平台分析

第7章 市場情況

  • 市場概要
  • 市場規模與預測

第8章 各給藥途徑市場區隔

  • 局部
  • 口服

第9章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 推動市場的要素

第11章 促進要素的影響

第12章 市場課題

第13章 促進要素及課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式
  • Anacor Pharmaceuticals
  • Galderma
  • Janssen Biotech
  • Novartis
  • Valeant Pharmaceuticals
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

圖表

目錄
Product Code: IRTNTR8747

About Dermatophytic Onychomycosis

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

Technavio's analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.

The market is divided into the following segments based on geography:

  • APAC
  • EMEA
  • Americas

Technavio's report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Anacor Pharmaceuticals
  • Galderma
  • Janssen Biotech
  • Novartis
  • Valeant Pharmaceuticals

Other Prominent Vendors

  • Abeona Therapeutics
  • Allergan
  • Elorac
  • GlaxoSmithKline
  • Hexima
  • Hisamitsu Pharmaceutical
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharma
  • Moberg Pharma
  • NanoBio
  • NovaBiotics
  • Nuvo Research
  • Pfizer
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Taro Pharmaceutical
  • Topica Pharmaceuticals
  • Viamet Pharmaceuticals

Market driver

  • Increase in R&D
  • For a full, detailed list, view our report

Market challenge

  • Adverse effects and limited efficacy of drugs
  • For a full, detailed list, view our report

Market trend

  • Increased focus on combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Product offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Overview: Dermatophytic onychomycosis

  • Types of dermatophytic onychomycosis
  • Risk factors
  • Management
  • Epidemiology

PART 06: Pipeline analysis

  • TDT 067
  • P-3058
  • MOB-015
  • VT-1161
  • Luliconazole solution, 10%
  • ME1111
  • NP213
  • HXP124

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by route of administration

  • Topical
  • Oral

PART 09: Geographical segmentation

  • Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
  • Dermatophytic onychomycosis market in Americas
  • Dermatophytic onychomycosis market in EMEA
  • Dermatophytic onychomycosis market in APAC

PART 10: Market drivers

  • Increase in R&D
  • Growing prevalence of dermatophytic onychomycosis
  • Unmet medical needs
  • Rise in prevalence of diabetes

PART 11: Impact of drivers

PART 12: Market challenges

  • Adverse effects and limited efficacy of drugs
  • Lack of awareness
  • Increased availability of generics and alternative therapies
  • Product recalls by US FDA

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Increased focus on combination therapies
  • Outsourcing of drugs manufacturing
  • Increase in strategic alliances among vendors
  • Incorporation of novel technology for product development

PART 15: Vendor landscape

  • Competitive scenario
  • Anacor Pharmaceuticals
  • Galderma
  • Janssen Biotech
  • Novartis
  • Valeant Pharmaceuticals
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
  • Exhibit 02: Percentage of population undergoing treatment globally 2015
  • Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
  • Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
  • Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
  • Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Comparison of activity of topical medications for onychomycosis
  • Exhibit 09: Comparison of activity of oral medications for onychomycosis
  • Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
  • Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
  • Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
  • Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
  • Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
  • Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
  • Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
  • Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
  • Exhibit 19: Impact of drivers
  • Exhibit 20: Impact of drivers and challenges
  • Exhibit 21: Anacor Pharmaceuticals: Key takeaways
  • Exhibit 22: Galderma: Key takeaways
  • Exhibit 23: Janssen Biotech: Key takeaways
  • Exhibit 24: Novartis: Key takeaways
  • Exhibit 25: Valeant Pharmaceuticals: Key takeaways
Back to Top